FiercePharma7d
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
Albuquerque Journal5d
FDA Warns Sanofi of Manufacturing Irregularities at Key Facility
The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current ...
STAT7d
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
Medical Xpress5d
FDA warns Sanofi of manufacturing irregularities at key facility
The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant ... their Genzyme manufacturing plant in Framingham, Massachusetts. On Jan. 15, 2025, a warning ...
McKnight's Senior Living6d
FDA warns Sanofi of manufacturing irregularities at key facility
The US Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients at their ...
ENDPOINTS NEWS7d
Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site
A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...
Becker's Hospital Review6d
FDA warns Sanofi over manufacturing violations
The FDA issued a warning letter to Sanofi regarding significant manufacturing violations at its Genzyme Corporation Facility in Framingham, Mass. The letter, dated Dec. 16, 2024, and amended Jan. 15, ...
The Financial Express9d
Sanofi to increase competition in atopic dermatitis market after Dupixent’s success
Sanofi‘s participation at the JP Morgan Healthcare Conference on January 14, 2025, was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future. The CEO ...
Business Insider8d
Sanofi’s Growth Prospects and Undervalued Position Highlighted by Analyst Graham Parry
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Buy rating on the ...